# US 2019/0375716 A1 · Piperidine derivatives as liver x receptor beta agonists, compositions, and their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375716 A1
- Document ID: US20190375716A1
- Status: Published application
- Kind: A1
- Application number: 16/341,591
- Filed: 2017-10-09
- Published: 2019-12-12
- Earliest claimed: 2016-10-14
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme Corp.
- Inventors: Michael T. Rudd; Zhaoyang Meng; Jenny Wai; David Jonathan Bennett; Edward J. Brnardic; Nigel J. Liverton; Shawn J. Stachel; Yongxin Han; Paul Tempest; Jiuxiang Zhu; Xuewang Xu; Bin Zhu; Chuanman Huang
- Web page: https://patentgrep.com/patent/US20190375716A1

## CPC

- A61P 9/00: Drugs for disorders of the cardiovascular system
- C07D 221/20: Spiro-condensed ring systems
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 211/16: with acylated ring nitrogen atom
- C07D 211/20: with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D 211/24: by sulfur atoms to which a second hetero atom is attached
- C07D 211/26: with hydrocarbon radicals, substituted by nitrogen atoms
- C07D 211/34: with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 211/96: Sulfur atom
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

In its many embodiments, the present invention provides certain piperidine compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R3, L, R4, L1, Q, and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

## Claims

### Claim 1

A compound having the structural Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
X is selected from CH and N;
Y is selected from NH, N(CH3), S, S(O), S(O)2 and CH2;
R1 is selected from H, methyl, and halogen;
R2 is selected from H, halogen, cyano, cyclopropyl, —CH3, and —OCH3;
R4 is selected from H, halogen, and methyl;
-L- is selected from —C(O)— and —S(O)2—;
R3 is —N(RN1)(RN2), wherein:
RN1 is selected from H and —(C1-C6)alkyl; and
RN2 is selected from H, —(C1-C6)alkyl, cyclopropyl, —O—(C1-C6)alkyl, —OH, halogen, —CN, and —(C1-C6)alkyl which is substituted with 1 or 2 groups independently selected from:
OH, halogen, —CN,
optionally substituted phenyl, (wherein said optional substitutents on said phenyl are 1 to 3 groups independently selected from OH, CN, —(C1-C4)alkyl, —(C1-C4)alkoxyl),
optionally substituted heteroaryl, (wherein said optional substituents on said heteroaryl are 1 to 3 groups independently selected from —(C1-C6)alkyl, —(C1-C4)alkoxyl, and cyclopropyl),
optionally substituted cyclopropyl (wherein said optional substituents on said cyclopropyl are 1 to 3 groups independently selected from —(C1-C6)alkyl), and
optionally substituted heterocycloalkyl (wherein said optional substitutents on said heterocycloalkyl are 1 to 3 groups independently selected from halogen, —OH, oxo, CN, and —(C1-C6)alkyl,
or, alternatively, RN1 and RN2 are taken together with the nitrogen atom to which they are shown attached to form a 4-, 5-, or 6-membered fully saturated heterocyclic ring comprising (including the nitrogen atom) 1, 2, or 3 ring heteroatoms selected from N, N-oxide, O, S, and S-oxide,
wherein said heterocyclic ring is unsubstituted or substituted with 1, 2, or 3 substituents independently selected from halogen, —OH, oxo, CN, —(C1-C6)alkyl, amino-substituted —(C1-C6)alkyl (wherein said amino is 1, 2, or 3 groups independently selected from —NH2, —N(C1-C4alkyl)2, and —NH(C1-C4alkyl)), —O—(C1-C6)alkyl, —(C1-C6)alkyl-OH, —(C1-C6)haloalkyl, —C(O)O—(C1-C6)alkyl, cyclopropyl, spirocyclopropyl, —CH2—NHC(O)O—(C1-C6)alkyl, —CH2—N(CH3)C(O)O—(C1-C6)alkyl, phenyl, benzyl, —NHC(O)-phenyl, heteroaryl, and —(C1-C4)alkylheteroaryl, heterocycloalkyl;
-L1- is a divalent moiety selected from:
Q is a bond or a divalent moiety selected from —C(O)—, —S(O)2—, and —C(O)O—; and
R5 is —C(R5A)(R5B)(R5C), wherein:
each of R5A, R5B and R5C is independently selected from: H, halogen, OH, NH2, NHCH3, —(C1-C6)alkyl, —(C1-C6)haloalkyl, —(C1-C6)alkenyl, —(C1-C6)alkynyl, —(C3-C6)cycloalkyl, —(C3-C6)cycloalkyl substituted with —(C1-C6)alkyl, —(C1-C6)alkenyl, —(C1-C6)alkynyl, phenyl, and phenyl substituted with from 1 to 3 groups independently selected from halogen, OH, —NH2, —(C1-C6)alkyl, —O—(C1-C6)alkyl, cyclopropyl, —O—(C1-C6)haloalkyl, —O-cyclopropyl, and —C(O)O—(C1-C6)alkyl,
or R5 is
wherein n is an integer from 1 to 4;
wherein R5D is selected from H, —(C1-C6)alkyl, —(C1-C6)haloalkyl, phenyl, and phenyl substituted with from 1 to 3 groups independently selected from OH, halogen, —(C1-C6)alkyl, and —O—(C1-C6)alkyl,
or R5 is selected from phenyl and benzyl, wherein:
said phenyl and said benzyl are unsubstituted or substituted with 1, 2, or 3 groups independently selected from halogen, CN, —(C1-C6)alkyl, and —(C1-C6)haloalkyl.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is CH.

### Claim 3 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is N.

### Claim 4 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R3 is —N(RN1)(RN2), wherein:
RN1 is selected from H, methyl, and ethyl; and
RN2 is H, methyl, ethyl, —O-methyl, —O-ethyl, OH, fluoro, chloro, —CN, substituted methyl, or substituted ethyl, wherein each said substituent is 1 or 2 groups independently selected from:
OH, fluoro, chloro, —CN,
optionally substituted phenyl, (wherein said optional substitutents on said phenyl are 1 to 3 groups independently selected from OH, CN, methyl, ethyl, —O-methyl, and —O-ethyl),
optionally substituted heteroaryl, (wherein said optional substituents on said heteroaryl are 1 to 3 groups independently selected from methyl, ethyl, —O-methyl, —O-ethyl, and cyclopropyl),
optionally substituted cyclopropyl (wherein said optional substituents on said cyclopropyl are 1 to 3 groups independently selected from methyl and ethyl,
optionally substituted heterocycloalkyl (wherein said optional substitutents on said heterocycloalkyl are 1 to 3 groups independently selected from halogen, —OH, oxo, CN, methyl, and ethyl, —O-methyl, —O-ethyl, —OH, F, Cl, and —CN.

### Claim 5 (depends on 4)

The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein R1 is selected from H, methyl, F, and Cl.

### Claim 6 (depends on 5)

The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein R2 is selected from H, Cl, cyano, cyclopropyl, —CH3, and —OCH3.

### Claim 7 (depends on 6)

The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein R4 is selected from H, —CH3, and chloro.

### Claim 8 (depends on 7)

The compound of claim 7, or a pharmaceutically acceptable salt thereof, wherein R5 is-C(R5A)(R5B)(R5C),
wherein each of R5A, R5B and R5C is independently selected from H, F, Cl, OH, NH2, NHCH3, —(C1-C6)alkyl, —(C1-C6)haloalkyl, —(C1-C6)alkenyl, —(C1-C6)alkynyl, —(C3-C6)cycloalkyl, —(C3-C6)cycloalkyl substituted with —(C1-C6)alkyl, —(C1-C6)alkenyl, —(C1-C6)alkynyl, phenyl, phenyl substituted with from 1 to 3 groups independently selected from F, Cl, —(C1-C6)alkyl, —O—(C1-C6)alkyl, and —C(O)O—(C1-C6)alkyl.

### Claim 9 (depends on 7)

The compound of claim 7, wherein R5 is
wherein n is an integer from 1 to 4; and R5D is selected from H, —(C1-C6)alkyl, —(C1-C6)haloalkyl, phenyl, and phenyl substituted with from 1 to 3 groups independently selected from OH, F, Cl, methyl, ethyl, n-propyl, i-propyl, —O-methyl, and —O-ethyl.

### Claim 10 (depends on 7)

The compound of claim 7, or a pharmaceutically acceptable salt thereof, wherein R5 is selected from phenyl and benzyl, wherein said phenyl and said benzyl are unsubstituted or substituted with 1, 2, or 3 groups independently selected from halogen, CN, —(C1-C6)alkyl, and —(C1-C6)haloalkyl.

### Claim 11 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, said compound selected from:

### Claim 12 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

### Claim 13 (depends on 1)

A method for the treatment of Alzheimer's Disease, Neimann-Pick disease type Cl, Parkinson's Disease, amyotrophic lateral sclerosis, stroke, age-related macular degeneration, schizophrenia, depression, cardiovascular disease, obesity or diabetes, said method comprising administering an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

### Claim 14

(canceled)

### Claim 15

(canceled)
